According to a market report by Lucintel, the future of the global B-cell lymphoma treatment market looks promising with opportunities in the hospital, specialty clinic, and home healthcare markets. The global B-cell lymphoma treatment market is expected to reach an estimated $10 billion by 2030, at a CAGR of 7.8% from 2024 to 2030. The major drivers for this market are growing incidence of B-cell lymphomas and on-going advancements in the treatment options.
A more
than 150-page report to understand trends, opportunity and forecast in global B-cell
lymphoma treatment market to 2030 by type (diffuse large B-cell lymphoma,
lymphoplasmacytic lymphoma, hairy cell leukemia, primary central nervous system
lymphoma, primary intraocular lymphoma, and others), end use (hospitals,
specialty clinics, home healthcare, and others), distribution channel (direct
tender, hospital pharmacy, retail pharmacy, online pharmacy, and others), and
region (North America, Europe, Asia Pacific, and the Rest of the World).
Lucintel
forecasts that diffuse large B-cell lymphoma will remain the largest segment
over the forecast period due to increase number of cases and growing prevalence
of B-cell lymphomas.
Within
this market, hospital will remain the largest segment as it provides necessary
equipment and expertise to perform a wide range of B-cell lymphoma treatments.
Download
sample by clicking on B-cell lymphoma treatment market
North
America will remain the largest segment over the forecast period due to
presence of well-developed healthcare system with access to the latest B-cell
lymphoma treatments in the region.
Pfizer,
Celgene Corporation, Eli Lilly, Novartis, Genentech, AstraZeneca, F.
Hoffmann-La Roche, Eisai, Amgen, Merck are the major suppliers in the B-cell lymphoma treatment market.
This unique research
report will enable you to make confident business decisions in this globally
competitive marketplace. For a detailed table of contents, contact Lucintel at
+1-972-636-5056 or write us at helpdesk@lucintel.com To get
access of more than 1000 reports at fraction of cost visit Lucintel's Analytics Dashboard.
About Lucintel
At Lucintel, we offer solutions for
you growth through game changer ideas and robust market &
unmet needs analysis. We are based in
Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20
years. We are quoted in several publications like the Wall Street Journal,
ZACKS, and the Financial Times.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. +1-972-636-5056
Explore Our Latest Publications
No comments:
Post a Comment